GERMANY — Recipharm has invested in a new high-speed filling line for pre-filled syringes and cartridges at its facility in Wasserburg, Germany responding to increased customer demand in these high-growth fill formats.
This investment, which is part of a larger program of recent investments and expansions across the company, will expand Recipharm’s comprehensive manufacturing offering for injectable products that require sterile filling.
The premier sterile manufacturing facility specializes in more complex formats such as lyophilization and aseptic filling into vials, syringes, and cartridges.
Recipharm’s manufacturing footprint will be expanded with the addition of a cutting-edge, high-speed filling line for pre-filled syringes and cartridges.
The line will be fully Annex 1 compliant and capable of handling both small and large-volume projects.
Earlier on, in a bid to establish itself in the advanced therapy medicinal products space, Recipharm completed the acquisitions of Arranta Bio, an advanced therapy contract development and manufacturing organization (CDMO), and Vibalogics, a virotherapy CDMO.
The acquisitions aid the company’s expansion into the biologics market, with a particular emphasis on drug substance manufacturing for novel advanced therapy medicinal products (ATMPs).
Recipharm entered the biologics market earlier this year with the acquisition of GenIbet, a Portuguese biopharmaceutical contract manufacturing organization (CMO).
The new acquisitions also allow Recipharm to establish a presence in the United States, with facilities in Boxborough, Massachusetts, and to provide a platform from which to expand its capabilities in new biologics modalities.
Elsewhere, Aragen Life Sciences, an Indian contract research development, and manufacturing organization has announced that it would operationalize its formulation manufacturing facility in Hyderabad, India, by 2023.
The new 12,000-square-foot facility will include dosage form capabilities for oral solids, liquids, topicals, and films, as well as manufacturing technologies for granulation, film coating, spray drying, and tableting, with plans to expand to include nano milling and hot melt extrusion capabilities.
According to a press release from the company, these new capabilities are intended to improve the company’s early-stage development offerings by providing more flexibility in terms of multiple dosage forms.
The facility will also include process technologies and batch sizes ranging from 1000 to 100,000 units.
Still on the CDMO front, the Aenova Group, a global contract manufacturing and development company, has announced a strategic partnership with Microcaps, a Swiss biotechnology start-up specializing in microencapsulation technology.
The collaboration’s goal is to speed up and improve the development and production of pharmaceuticals, food supplements, and other products.
Microcaps will use its patented microencapsulation technology platform, according to a company press release, to enable customized formulations such as release, protective coating, and texture, among other things.
This will enable Aenova to provide a broader range of new product development and life cycle management solutions for micro and conventional capsule formulations.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
Be the first to leave a comment